Hot Products
| Catalog No. | Information |
| CFN00258 | Rinderine Reference standards. |
| CFN00470 | Rinderine N-oxide |
| CFN92217 | Rivularin Reference standards. |
| CFN98780 | Robinetin Robinetin has antioxidant and antiradical activities, inhibits EYPC membrane lipid peroxidation and HbA glycosylation with high efficiency. Robinetin also has anti-mutagenesis and anti-promotion effects, diminishes ornithine decarboxylase activity induction at 6 h after 12-O-tetradecanoyl phorbol-13-acetate. Robinetin leads to the occurrence of positive induced circular dichroism (ICD) bands in the near ultra-violet (UV) region. |
| CFN98375 | Robinin Robinin has cardioprotective effect on doxorubicin-induced cardiac toxicity by modulating TGF-β1 signaling pathway in Sprague Dawley rats. Robinin has protective effect against the ox-LDL induced inflammation stress in hPBMCs by inhibiting TLR4-NF-κB signaling pathway. |
| CFN97767 | Robtein Reference standards. |
| CFN98672 | Robtin Reference standards. |
| CFN98562 | Roburic acid Roburic acid and phenethyl-trans-ferulate inhibit COX-1 and COX-2. |
| CFN96362 | Robustine Robustine may have anti-inflammatory activity, it exhibits inhibition (IC 50 < or = 18.19 microM) of superoxide anion generation by human neutrophils in response to formyl- l-methionyl- l-leucyl- l-phenylalanine/cytochalasin B (FMLP/CB). |
| CFN97339 | Rocaglamide Rocaglamides are potent natural anticancer products that inhibit proliferation of various cancer cells at nanomolar concentrations, it prevents tumor growth and sensitize resistant cancer cells to apoptosis by blocking the MEK-ERK-eIF4 pathway. Rocaglamides can suppress the PMA-induced expression of NF-kappaB target genes and sensitize leukemic T cells to apoptosis induced by TNFalpha, cisplatin, and gamma-irradiation, suggests that rocaglamide derivatives could serve as lead structures in the development of anti-inflammatory and tumoricidal drugs. Rocaglamide and a XIAP inhibitor cooperatively sensitize TRAIL-mediated apoptosis in Hodgkin's lymphomas. |
